RVL Pharmaceuticals plc. announced its preliminary second quarter FY22 sales from Upneeq of $8.4 million. The figure represents a +42% growth sequentially.
Upneeq is an approved ophthalmic solution for droopy eyelids.
The company also mentioned that it had received orders from approximately 2,200 cumulative unique medical aesthetics practices from February through June of 2022.
CEO Brian Markison said, “ As planned and previously announced, we expect to significantly expand our medical aesthetics salesforce by mid to late July and believe that we are well-positioned to build on our momentum and achieve our fourth quarter 2022 net sales projection."
RVL reaffirmed its outlook on Q4 Upneeq sales in the range of $20 million to $25 million.